Sinclair Pharma PLC (LON:SPH) insider Alan Olby purchased 6,748 shares of Sinclair Pharma PLC stock in a transaction dated Monday, November 14th. The stock was bought at an average price of GBX 29 ($0.36) per share, with a total value of £1,956.92 ($2,444.93).

Sinclair Pharma PLC (LON:SPH) opened at 29.00 on Friday. The firm’s 50-day moving average is GBX 28.48 and its 200 day moving average is GBX 30.66. The stock’s market cap is GBX 144.13 million. Sinclair Pharma PLC has a one year low of GBX 26.00 and a one year high of GBX 61.33.

A number of equities analysts recently issued reports on SPH shares. Stifel Nicolaus reissued a “buy” rating and issued a GBX 49 ($0.61) price objective on shares of Sinclair Pharma PLC in a report on Thursday, September 1st. Peel Hunt reissued a “buy” rating and issued a GBX 68 ($0.85) price objective on shares of Sinclair Pharma PLC in a report on Wednesday, September 21st. N+1 Singer reissued a “buy” rating on shares of Sinclair Pharma PLC in a report on Wednesday, October 5th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Sinclair Pharma PLC in a report on Thursday, September 15th. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of GBX 57 ($0.71).

Sinclair Pharma PLC Company Profile

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Stock Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related stocks with our FREE daily email newsletter.